Renal Fanconi syndrome with meropenem/amoxicillin-clavulanate during treatment of extensively drug-resistant tuberculosis,European Respiratory Journal

当前位置： X-MOL 学术 › Eur. Respir. J. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Renal Fanconi syndrome with meropenem/amoxicillin-clavulanate during treatment of extensively drug-resistant tuberculosis
European Respiratory Journal ( IF 24.3 ) Pub Date : 2017-12-01 , DOI: 10.1183/13993003.02023-2017
Miriam E. Abadie , Jeffrey R. Strich , Tiffany Kim , Yingda L. Xie , Kevin P. Fennelly , Kenneth N. Olivier , Meryl Waldman , Kriti Arora , Steven M. Holland , Ray Y. Chen

We read with interest the papers by Tiberi et al. [1, 2] describing the effectiveness of meropenem/clavulanate in treating multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) patients. In these analyses, 96 patients were treated with meropenem/clavulanate for a median of 85 (interquartile range (IQR) 49–156) days with six adverse events, and 84 patients were treated with imipenem/clavulanate for a median (IQR) of 187 (60–428) days and three adverse events, none renally related. We report a patient with XDR-TB who developed renal Fanconi syndrome apparently due to meropenem/amoxicillin-clavulanate. Prolonged use of meropenem/amoxicillin-clavulate to treat XDR-TB may be associated with renal Fanconi syndrome http://ow.ly/dFSD30gCKti

中文翻译：

美罗培南/阿莫西林-克拉维酸治疗广泛耐药结核病期间的肾范可尼综合征

我们饶有兴趣地阅读了 Tiberi 等人的论文。[1, 2] 描述了美罗培南/克拉维酸治疗耐多药 (MDR) 和广泛耐药 (XDR) 结核病 (TB) 患者的有效性。在这些分析中，96 名患者接受了美罗培南/克拉维酸治疗的中位时间为 85（四分位距（IQR）49-156）天，发生了 6 次不良事件，84 名患者接受了亚胺培南/克拉维酸治疗的中位（IQR）为 187 (60–428) 天和三个不良事件，均与肾脏无关。我们报告了一名 XDR-TB 患者，该患者显然由于美罗培南/阿莫西林-克拉维酸盐而出现肾范可尼综合征。长期使用美罗培南/阿莫西林克拉维酸盐治疗 XDR-TB 可能与肾范可尼综合征有关 http://ow.ly/dFSD30gCKti

更新日期：2017-12-01

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>